Additionally, we have demonstrated that pharmacologic inhibition of KDM6B in Asxl1-mutant HSPCs restores H3K27me3 level, normalizes leukemogenic gene expression and HSPC function, and reduces the tumor burden in mouse models of ASXL1 mutation–mediated leukemia. Here, KDM6B is linked to neoplasm.